

Total Synthesis of 7-Deoxypancratistatin-1-carboxaldehyde and Carboxylic Acid via Solvent-Free Intramolecular Aziridine Opening: Phenanthrene to Phenanthridone Cyclization Strategy


Jonathan Collins, Melissa Drouin, Xuetong Sun, Uwe Rinner,[‡] and
Tomas Hudlicky*

Department of Chemistry and Centre for Biotechnology, Brock University, 500
Glenridge Avenue, St. Catharines, Ontario L2S 3A1, Canada

thudlicky@brocku.ca

Received October 6, 2007

ABSTRACT



Solid-state silica-gel-catalyzed opening of aziridine 6 provided phenanthrene 7, whose oxidative cleavage, recyclization, and further elaboration furnished the C-1 aldehyde and carboxylic acid derivatives of 7-deoxypancratistatin for potential analogue synthesis.

Since the first asymmetric synthesis of pancratistatin that we published in 1995,¹ we have devoted considerable effort to multigenerational design of and improvements² in approaches to the total synthesis of Amaryllidaceae constituents³ and their unnatural derivatives.⁴ In collaboration with Pettit's group at Arizona State University, we have focused on designs to produce a variety of derivatives⁵ containing

the minimum pharmacophore but with better bioavailability or solubility than the otherwise very potent natural products such as pancratistatin (1), narciclasine (2), or their 7-deoxy analogues 7-deoxypancratistatin (3) and lycoricidine (4). These constituents are shown in Figure 1 along with an indication of the structural requirements for activity as elucidated through the efforts of Pettit and others.⁶

[‡] Current address: Department of Organic Chemistry, University of Vienna, Währinger Strasse 38, 1090 Vienna, Austria.

(1) (a) Tian, X.; Hudlicky, T.; Koenigsberger, K. *J. Am. Chem. Soc.* **1995**, *117*, 3643. (b) Hudlicky, T.; Tian, X.; Koenigsberger, K.; Maurya, R.; Rouden, J.; Fan, B. *J. Am. Chem. Soc.* **1996**, *118*, 10752.

(2) For improved preparations see: (a) Tian, X.; Maurya, R.; Koenigsberger, K.; Hudlicky, T. *Synlett* **1995**, 1125 (7-deoxypancratistatin). (b) Akgun, H.; Hudlicky, T. *Tetrahedron Lett.* **1999**, *40*, 3081 (*ent*-7-deoxypancratistatin). (c) Gonzalez, D.; Martinot, T.; Hudlicky, T. *Tetrahedron Lett.* **1999**, *40*, 3077 (narciclasine). (d) Hudlicky, T.; Olivo, H. F. *J. Am. Chem. Soc.* **1992**, *114*, 9694 (lycoridine). (e) Hudlicky, T.; Olivo, H. F.; McKibben, B. *J. Am. Chem. Soc.* **1994**, *116*, 5108 (lycoridine). (f) Rinner, U.; Siengalewicz, P.; Hudlicky, T. *Org. Lett.* **2002**, *4*, 115 (*epi*-7-deoxypancratistatin).

(3) For reviews on synthesis of Amaryllidaceae constituents see: (a) Chapleur, Y.; Chretien, F.; Ahmed, S. I.; Khaldi, M. *Curr. Org. Syn.* **2006**, *3*, 341. (b) Rinner, U.; Hudlicky, T. *Synlett* **2005**, 365. (c) Jin, Z. *Nat. Prod. Rep.* **2003**, *20*, 606. (d) Hoshino, O. In *The Alkaloids*; Cordell, G. A., Ed.; Academic Press: New York, 1998; Vol. 51, pp 323–424. (e) Polt, R. In *Organic Synthesis: Theory and Applications*; Hudlicky, T., Ed; JAI Press: Greenwich, CT, 1997; Vol. 3, p 109. (f) Martin, S. F. In *The Alkaloids*; Brossi, A. R., Ed.; Academic Press: New York, 1987; Vol. 40, p 251. (g) Fuganti, C. *The Alkaloids*; Manske, R. H. F., Ed.; Academic Press: New York, 1975; Vol. 10, Chapter 3, pp 83–164. (h) Wildman, W. C. In *The Alkaloids*; Manske, R. H. F., Ed.; Academic Press: New York, 1968; Chapter 10, pp 307–406. (i) Cook, J. W.; Loudon, J. D. In *Alkaloids of the Amaryllidaceae, The Alkaloids*; Manske, R. H. F., Holmes, H. L., Eds.; Academic Press: New York, 1952; Vol. II, Chapter XI, pp 331.




Figure 1. Pancratistatin and congeners; the structural and functional requirements for a minimum pharmacophore.

Pancratistatin and narciclasine are highly active against many cancer cell lines: murine P388 lymphocytic leukemia; human cancer cells: pancreas BXP-3, breast MCF-7, CNS SF-268, lung NCI-H460, colon KM20L2, and prostate DU-145. Although the exact mode of action remains unknown for pancratistatin, narciclasine is believed to inhibit peptide bond formation in eukaryotic ribosomes.⁷ Lycoricidine and 7-deoxypancratistatin are significantly less active, probably because of the absence of the hydrogen-bonded donor–acceptor pair in the phenanthridone functionality.

As C-1 substitution does not appear to be detrimental to biological activity,⁸ we considered preparation of compounds with varied functionality at this position. To this end we envisioned a new approach that would provide an aldehyde functionality at C-1, well suited for further derivatization. The new strategy, portrayed in Figure 2, is based on the recently discovered solid-state silica-gel-catalyzed opening of aziridines with carbon nucleophiles.^{4c} The approach relies on the regioselective opening of epoxy aziridine **5**^{9,2f} with




Figure 2. Design strategy toward 7-deoxypancratistatin and its C-1 analogues based on oxidative cleavage of the phenanthrene core and recyclization to the phenanthridone.

aluminum acetylide, reduction of the alkyne to the cis olefin in **6**, solid-state cyclization to the complete phenanthrene core **7**, and oxidative cleavage with concomitant recyclization and selective oxidation to the phenanthridone **8**, which possesses the complete nucleus of pancratistatin-type compounds. The recyclization strategy not only provides the C-1 aldehyde for further functionalization and production of analogues but also allows the conversion of this compound to 7-deoxypancratistatin by a more efficient protocol than used in our previous syntheses. In this manuscript we report the total synthesis of the C-1 carboxylic acid analogue of 7-deoxypancratistatin and outline the potential of a library-type approach to C-1 derivatives from aldehyde **8**.

The synthesis began with the preparation of homochiral epoxy aziridine **5**⁹ from bromobenzene by previously established protocols.¹⁰ Selective opening of the oxirane ring was accomplished with the aluminum acetylide derived from **11**, generated *in situ*, providing after protection the silyl ether **12**. Borane reduction furnished the cis alkene **6**, which was adsorbed on silica^{4c} and heated without solvent at 120 °C for 24 h to provide a 52% yield of phenanthrene **7**, as shown in Scheme 1.

Phenanthrene **7** was converted to the phenanthridol skeleton **15** either by direct ozonolysis of **7** or by a three-step procedure consisting of OsO₄-mediated oxidation to the stage of over-oxidized keto alcohol **13** (OsO₄/NMO, 89%), followed by reduction and periodate cleavage to dialdehyde **14**, which immediately cyclized to the hemiaminal **15**. The three-step procedure produced **15** in an overall yield of 82% from **7**. Oxidation with IBX provided the complete phen-

(4) See for example: (a) Hudlicky, T.; Rinner, U.; Gonzalez, D.; Akgun, H.; Schilling, S.; Siengalewicz, P.; Martinot, T. A.; Pettit, G. R. *J. Org. Chem.* **2002**, *67*, 8726 (truncated derivatives). (b) Rinner, U.; Hudlicky, T.; Gordon, H.; Pettit, G. R. *Angew. Chem., Int. Ed.* **2004**, *43*, 5342 (indole-containing mimic). (c) Hudlicky, T.; Rinner, U.; Finn, K. J.; Ghiviriga, I. *J. Org. Chem.* **2005**, *70*, 3490 (indole-containing mimic). (d) Rinner, U.; Hillebrenner, H. L.; Adams, D. R.; Hudlicky, T.; Pettit, G. R. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 2911 (truncated derivatives). (e) Ibn-Ahmed, S.; Khaldi, M.; Chretien, F.; Chapleur, Y. *J. Org. Chem.* **2004**, *69*, 6722 (lactone mimics of lycoricidine and pancratistatin).

(5) For recent library type approaches to pancratistatin derivatives by cyclotrimerization strategy see: (a) Moser, M.; Sun, X.; Hudlicky, T. *Org. Lett.* **2005**, *7*, 5669. (b) Hudlicky, T.; Moser, M.; Banfield, S. C.; Rinner, U.; Chapuis, J.-C.; Pettit, G. R. *Can. J. Chem.* **2006**, *84*, 1313.

(6) (a) Pettit, G. R.; Freeman, S.; Simpson, M. J.; Thompson, M. A.; Boyd, M. R.; Williams, M. D.; Pettit, G. R., III; Doubek, D. L. *Anti-Cancer Drug Design* **1995**, *10*, 243. (b) McNulty, J.; Larichev, V.; Pandey, S. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 5315.


(7) Baez, A.; Vazquez, D. *Biochim. Biophys. Acta* **1978**, *518*, 95.

(8) (a) Pettit, G. R.; Melody, N.; Herald, D. L. *J. Nat. Prod.* **2004**, *67*, 322. (b) McNulty, J.; Mao, J.; Gibe, R.; Mo, R.; Wolf, S.; Pettit, G.; Herald, D.; Boyd, M. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 169. (c) McNulty, J.; Larichev, V.; Pandey, S. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 5315.

(9) Schilling, S.; Rinner, U.; Chan, C.; Ghiviriga, I.; Hudlicky, T. *Can. J. Chem.* **2001**, *79*, 1659.

(10) For large-scale preparation of diene diol **10** by fermentation with *Escherichia coli* JM109(pDTG601) see: Endoma, M. A.; Bui, V. P.; Hansen, J.; Hudlicky, T. *Org. Process Res. Dev.* **2002**, *6*, 525.

Scheme 1



athridone skeleton **16** in six steps from epoxy aziridine **5** or ten steps from bromobenzene. Further oxidation of the




Figure 3. Conversion of C-1 carboxylic acid to 7-deoxypancratistatin.

aldehyde with *m*-CPBA furnished in 85% yield the C-1 carboxylic acid **17**, which was then elaborated to the fully hydroxylated stage of **20**. Because of the polarity of the final product, subsequent preparation proceeded to the methyl ester **18**, obtained in 83% yield from acid **17** by treatment with diazomethane. Ester **18** was then converted to the fully hydroxylated species **19** by reductive desotylation and deprotection prior to the final hydrolysis with LiOH in MeOH. The synthesis of the C-1 acid proceeded in 15 steps from bromobenzene.

Future efforts will focus on the conversion of **19** by oxidative decarboxylation¹¹ to the conduramine derivative **21**, a compound whose *N*-methoxybenzyl derivative has been converted to 7-deoxypancratistatin,¹² Figure 3. Aldehyde **16**

(11) (a) Hara, S.; Taguchi, H.; Yamamoto, H.; Noxaki, H. *Tetrahedron Lett.* **1975**, *19*, 1545. (b) Wender, P.; Singh, S. *Tetrahedron Lett.* **1990**, *31*, 2517.

(12) Padwa, A.; Zhang, H. *J. Org. Chem.* **2007**, *72*, 2570.

will be subjected to reductive amination protocols, and the acquired derivatives will be tested for biological activities and improved solubility. We will report on these endeavors in due course.

Acknowledgment. We are grateful to the following agencies for financial support: Natural Science and Engineering Research Council (NSERC), TDC Research Foundation, Canada Foundation for Innovation (CFI), Ontario Innovation Trust (OIT), Research Corporation, TDC Research, Inc., and Brock University. We also thank Dr. Ion

Ghiviriga (University of Florida) for his help in stereochemical assignment of **13**, Solomon Fixon-Owoo (Brock University) for preliminary synthesis of **13**, and Dr. Michael Moser (Brock University) for the elucidation of reaction events from **7** to **15**.

Supporting Information Available: Experimental procedures and spectral data for key compounds **12–20**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL702440F